Spark Therapeutics (ONCE) Misses Q3 EPS by 28c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
B.Riley/FBR Upgrades Spark Therapeutics (ONCE) to Buy
November 7, 2018 3:47 AM ESTB.Riley/FBR analyst Madhu Kumar upgraded Spark Therapeutics (NASDAQ: ONCE) from Neutral to Buy with a price target of $71.00 (from $68.00).
For an analyst ratings summary and ratings history on Spark Therapeutics click here. For more ratings news on Spark Therapeutics click here.
Shares of Spark Therapeutics closed at $41.68 yesterday.
... MoreSpark Therapeutics (ONCE) PT Lowered to $48 at BMO Capital
November 6, 2018 3:55 PM ESTBMO Capital analyst Matthew Luchini lowered the price target on Spark Therapeutics (NASDAQ: ONCE) to $48.00 (from $60.00) while maintaining a Market Perform rating.
The analyst believes weakness in the stock reflects continued uncertainty on the outlook for SPK-8011 for hemophilia A.
"We... More
